CPX-351 (Vyxeos) demonstrated improved overall survival (OS) at 5 years versus standard 7+3 chemotherapy in older patients with newly diagnosed, high-risk or secondary acute myeloid leukemia (AML) who achieved a complete response (CR) or a CR with incomplete hematologic recovery (CRi), or who...
72 had no resection: advanced disease (n=31), unfit from cardiorespiratory disease (n=28), primary treatment chemo/radiotherapy (n=6), patient refusal (n=2), complications during staging (n=3) and death (n=2). The mean AT in those undergoing surgery was 10.9 ± 3.4 compared to 8.6 ...
Considering that autophagy regulates the proliferation, migration and even chemo-sensitivity of cancer cells, we wondered whether the induction of autophagy by CPX affected its anti-cancer effects. HeLa and SiHa cells were treated with CPX combined with autophagy inhibitor CQ. Compared to CPX alone,...
25 (35%) patients had been previously diagnosed with another neoplasia, 23 of them had already received chemo or radiotherapy. Notably, four patients had prior autologous hematopoietic stem cell transplan- tation for low grade lymphoma (n. two patients) and multiple myeloma (n. two patients). ...
Background: Despite high response rates to front‐line chemoimmunotherapy, patients with follicular lymphoma (FL) inevitably relapse and further treatment ... C Ujjani,H Wang,L Leslie,... - 《Hematological Oncology》 被引量: 0发表: 2019年 Safety and efficacy of gemtuzumab ozogamicin and venetocl...